The decision to limit the prescription of cannabidiol for the treatment of certain conditions remains in force
After receiving criticism from patients and doctors for Resolution 2,324/2022, which limits the possibilities of prescribing medicines that contain cannabidiol, the Federal Council of Medicine (CFM) reported, on Thursday (10/20), that it will open a new public consultation to receive suggestions that will support a new document on this topic.
The controversial decision was published last Friday (10/14) and sparked protests among patients and relatives to limit the use of cannabidiol to treat epilepsy related to Dravet and Lennox-Gastaut syndromes and tuberous sclerosis complex. The rule excluded patients who had used CBD for other medicinal purposes, such as Parkinson’s disease and Alzheimer’s disease, and to treat chronic pain, anxiety and depression.
During its defense, the Center highlighted that for the preparation of the document it evaluated nearly 6,000 scientific articles published in important national and international journals. The results indicated “still fragile evidence” on the safety and efficacy of cannabidiol for the treatment of diseases.
According to the entity, CBD-approved prescription diseases are the only diseases for which there is more consistent evidence.
Those interested in participating in the new public consultation between October 24 and December 23, 2022 must send suggestions through a platform created by CFM. They must inform the CPF number, state and municipality of residence. The data will be confidential and will remain anonymous.
According to the Council of Foreign Ministers, Resolution No. 2324/2022 was also based on public consultation. Unlike the first public consultation, individuals may participate in the current consultation.